Loading clinical trials...
Loading clinical trials...
A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel
Conditions
Interventions
custirsen sodium
docetaxel
+1 more
Start Date
April 4, 2003
Primary Completion Date
March 9, 2006
Completion Date
December 21, 2009
Last Updated
August 4, 2023
NCT07547774
NCT07040891
NCT06257264
NCT05491226
NCT06492759
NCT03488693
Lead Sponsor
NCIC Clinical Trials Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions